The Department of Hematology and Medical Oncology (HMO) and the Winship Cancer Institute at Emory University proposes a T32 Translational Physician-Scientist Training Program in Oncology. This 2.5-year Training Program (including 6 months funded internally by the HMO Department, and 2 years of T32 funding support) will enable hematology/oncology fellows to acquire a strong education in basic/translational research approaches, with the ultimate goal of establishing an independent research program for each trainee. Many studies have documented the attrition of the physician-scientist pipeline, due in large part to the challenges faced in obtaining grant funding. Providing a high level of mentoring and support is necessary to nurture the development of young physician-scientists and retain them in academic institutions. The Training Program aims to (1) provide a sufficiently large mentor pool from which to select the most appropriate research topic(s) for each trainee; (2) foster a multidisciplinary approach to cancer care and patient-oriented research through interaction with basic and clinical investigators of diverse specialties; (3) provide guidance in research design, methodology and analysis that will foster the independence of developing physician-scientists in the field of translational oncology, focused on solid tumors mainly including head and neck, lung, breast, gastrointestinal and genitourinary malignancies; and (4) guide trainees through the development and submission of their first grant application(s). The Training Program will recruit 2 residents per year with 2-3 years of prior clinical training in internal medicine, a strong desire to develop basic science research skills in oncology, and a commitment to academic medicine. All trainees will initially be recruited to the existing Hematology/Oncology Fellowship Program, and will first complete 18 months of clinical requirements for the fellowship in PGY-4 and the first half of PGY-5 (to fulfill the board eligibilty requirements of the ACGME). Trainees will then undertake 2.5 years of T32 Training Program research, from the second half of PGY-5 through PGY-7, which will encompass close mentoring in research design, methodology and analysis, support in career development and grant preparation, and participation in a rigorously defined training curriculum. Training will focus on elements critical for a successful academic career, particularly progress towards conference presentations, manuscript publications, and applications for independent research funding. Through its strong commitment to the proposed Translational Physician-Scientist Training Program in Oncology, the Emory HMO Department and the Winship intend to actively contribute to training and mentoring the next generation of physician-scientist oncologists, supporting them in the early steps of their academic research careers.
Physician-scientists play a crucial role in bringing new discoveries from the laboratory to the clinic, ultimately bringing new treatment options to patients. Emory University proposes a 2.5-year training program to train young physicians in laboratory cancer research. By providing intensive research training, guided by experienced physicians, scientists and physician-scientists, this training program aims to support the next generation of physician-scientists in the early steps of their careers.
|Chang, Andres; Schlafer, Danielle; Flowers, Christopher R et al. (2018) Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. Expert Opin Investig Drugs 27:55-70|
|Chen, Qiushi; Staton, Ashley D; Ayer, Turgay et al. (2018) Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. Leuk Lymphoma 59:1700-1709|
|Zhang, Jun; Nannapaneni, Sreenivas; Wang, Dongsheng et al. (2017) Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status. Oncotarget 8:59008-59022|
|Li, Rui; Ding, Chunyong; Zhang, Jun et al. (2017) Modulation of Bax and mTOR for Cancer Therapeutics. Cancer Res 77:3001-3012|
|Smith, Demetria J; Sekhar, Aarti; Memis, Bahar et al. (2017) Rosai-Dorfman Disease Manifesting as a Pancreatic Head Mass Diagnosed Nonoperatively. J Oncol Pract 13:61-62|
|DeFilipp, Z; Rosand, C B; Goldstein, D A et al. (2017) Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors. Bone Marrow Transplant 52:132-134|
|Staton, Ashley D; Langston, Amelia A (2017) Autologous Stem Cell Transplant: Still the Standard for Fit Patients With Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk 17S:S96-S99|
|Staton, Ashley D; Cohen, Jonathon B (2016) A Clinician's Approach to Double-Hit Lymphoma: Identification, Evaluation, and Management. J Oncol Pract 12:232-8|
|Zeichner, Simon B; Terawaki, Hiromi; Gogineni, Keerthi (2016) A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer. Breast Cancer (Auckl) 10:25-36|
|Zhang, Jun; Park, Dongkyoo; Shin, Dong M et al. (2016) Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities. Acta Biochim Biophys Sin (Shanghai) 48:11-6|
Showing the most recent 10 out of 24 publications